Thomson Reuters Announces Nominations for Top BioPharma Deals of the Year

PHILADELPHIA, PA, UNITED STATES - Mar 10, 2015 - The Intellectual Property and Science business of Thomson Reuters, the world’s leader in intelligent information for businesses and professionals, has unveiled the nominations for the Allicense 2015 Breakthrough Awards, honoring the leading  deals of 2014 in Biopharmaceutical Licensing and  Mergers and Acquisitions (M&A), as identified by Thomson Reuters Recap, the leading provider of analysis and advice for biopharmaceutical business development. The awards-to be determined by public vote-will be presented on Tuesday, May 5 at Allicense, a prominent event connecting business development, licensing and M&A professionals throughout pharma, biotech and finance to discuss industry-wide challenges and collaborate on creating a roadmap for the future of pharmaceutical development.

The award nominees-five contenders in each of the two categories-were determined by Thomson Reuters deals analysts after a thorough analysis of Recap information and other criteria that examined numerous deals negotiated throughout 2014.

Members of the biopharmaceutical community are invited to vote for the top breakthrough deals in each category until 6 p.m. PT on Tuesday, May 5.

Nominees:

LICENSING:

Licensee & Licenser; Subject

AbbVie and Calico; Therapies for age-related diseases, including neurodegeneration and cancer

Regeneron and Avalanche; Gene therapy for ophthalmologic diseases

Takeda and Macro-Genetics; Protein targeting CD32B and CD79B for autoimmune diseases

Pfizer and Spark; Gene therapy program for hemophilia B

Sanofi and MyoKardia; Therapies for genetic heart diseases, hypertrophic and dilated cardiomyopathy

M&A:

Buyer; Seller

Actavis; Allergan

Janssen; Alios

Roche/Genentech; Seragon

Teva; Labrys

Accorda; Civitas

“We are excited to announce the nominees for the Allicense 2015 Breakthrough Awards for Deals of the Year and to honor these dealmakers that have been critical in driving our industry forward,” said Eric Walczykowski, vice president of Life Sciences at Thomson Reuters. “We welcome the members of the biopharma community to join us in determining the 2014 deals that most exemplify courageous innovation.”

Allicense will be held on May 5-6 in San Francisco. Visit Allicense.com to learn more about this key industry event, how you can register and the details behind the nominations. Cast your vote today!

Learn more about Thomson Reuters Recap and other competitive intelligence and deal-making solutions for Life Sciences.

Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. For more information, go to www.thomsonreuters.com.

Jen Breen
+1 215 823 1791
Jennifer.breen@thomsonreuters.com

Molly Malone
+1 215 823 3702
molly.malone@thomsonreuters.com